Tam Anh General Hospital (Oncology Center)
WebsiteOverview
Bệnh viện Đa khoa Tâm Anh (Tam Anh General Hospital) is a Vietnamese private hospital system founded in 2007, now running several high-technology hospitals and clinics in Hanoi and Ho Chi Minh City (including Tâm Anh Hanoi and Tâm Anh Ho Chi Minh City), with an oncology centre operating in both cities.
The hospital is building a new 1,000-bed general and cancer hospital in Phú Mỹ Hưng, District 7, Ho Chi Minh City (expected to be completed around 2028), which will house the first proton therapy system in Vietnam.
In February 2026, the Diagnostic Imaging and Interventional Radiology Centre at Tâm Anh Ho Chi Minh City became the first unit in Ho Chi Minh City and the southern region (public or private) to achieve ISO 15189:2022 accreditation for diagnostic imaging.
Scale
Beds: 480 (Tâm Anh Ho Chi Minh City); the new Phú Mỹ Hưng cancer hospital: 1,000 beds (expected around 2028) Cancer cases treated per year: not publicly disclosed
Accreditation
ISO 15189:2022 (Diagnostic Imaging and Interventional Radiology, February 2026 — the first in Ho Chi Minh City and the southern region). No JCI accreditation.
Strengths and key treatments
The first proton therapy system in Vietnam — Mevion S250-FIT (seated position); the partnership was announced in 2026 and the system is expected to be installed in early 2027 at the new Phú Mỹ Hưng cancer hospital.
Elekta Versa HD linear accelerator with Monaco planning software.
Da Vinci Xi surgical robot — the first in Vietnam to combine Single-Site and Dual Console technology.
PET/CT (Discovery IQ), AI-integrated 3T MRI, and AI-assisted 1,975-slice CT (Somatom Force VB30) for early cancer detection.
Oncologists
Director of the Oncology Center (Tam Anh Ho Chi Minh City); medical oncology (~40 years of experience); Vice President of the Vietnam Cancer Association; President of the Ho Chi Minh City Cancer Association.
Head of the Department of Oncology (Tam Anh Hanoi); oncology and nuclear medicine; member of ASCO, ESMO and IASLC (more than 20 years of experience).
Deputy Director of the Oncology Center; chemotherapy and molecular biology (more than 20 years of experience).